Ciclo celular/Ponto de verificação
Os inibidores do ciclo celular/ponto de verificação são compostos que interrompem a progressão normal do ciclo celular, particularmente em pontos de verificação regulatórios chave. Esses inibidores são cruciais para estudar a divisão celular, entender a proliferação de células cancerígenas e desenvolver terapias anticâncer. Ao direcionar fases específicas do ciclo celular, esses inibidores podem induzir a parada do ciclo celular, levando à apoptose ou senescência em células de divisão rápida. Na CymitQuimica, oferecemos uma ampla gama de inibidores de alta qualidade do ciclo celular/ponto de verificação para apoiar sua pesquisa em biologia do câncer, biologia celular e desenvolvimento de medicamentos.
Subcategorias de "Ciclo celular/Ponto de verificação"
- Aurora Quinase(94 produtos)
- CDK(500 produtos)
- Ciclo celular/Parada(4 produtos)
- Chk(42 produtos)
- DYRK(48 produtos)
- Dinamina(23 produtos)
- Ferroptose(215 produtos)
- HSP(169 produtos)
- Integrinas(224 produtos)
- Cinesina(66 produtos)
- LIM Quinase(19 produtos)
- Microtúbulo associado(261 produtos)
- PKC(102 produtos)
- PLK(28 produtos)
- ROCK(69 produtos)
- Rho(2 produtos)
- Wee1(15 produtos)
- c-Myc(69 produtos)
Exibir 10 mais subcategorias
Foram encontrados 3480 produtos de "Ciclo celular/Ponto de verificação"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cdk1/2 Inhibitor III
CAS:<p>Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor with an IC50 value of 2.1 μM against CDK1/cyclin B.</p>Fórmula:C15H13F2N7O2S2Pureza:99.07%Cor e Forma:SolidPeso molecular:425.44DHX9-IN-2
CAS:<p>DHX9-IN-2 is an inhibitor targeting ATP-dependent RNA de-helicase A (DHX9) with anticancer and antitumor activity for cancer research.</p>Fórmula:C18H16ClN3O3S2Pureza:98%Cor e Forma:SolidPeso molecular:421.92Plogosertib
CAS:<p>Plogosertib (CYC140) is a PLK1 inhibitor with an IC50 value of 3 nM.Plogosertib is antiproliferative and can be used to study solid and hematologic tumors.</p>Fórmula:C34H48N8O3Pureza:99.22% - 99.85%Cor e Forma:SolidPeso molecular:616.797SMN-C3
CAS:<p>SMN-C3 (MV8T2MCK57) is an orally active modulator of SMN2 splicing, and has the potential to treat spinal muscular atrophy (SMA).</p>Fórmula:C24H28N6OPureza:99.01% - 99.05%Cor e Forma:SolidPeso molecular:416.52LY3295668
CAS:<p>LY3295668 (AK-01) is a selective inhibitor of Aurora A with Kis of 0.8 nM and 1038 nM for Aurora A and B, respectively.</p>Fórmula:C24H26ClF2N5O2Pureza:99.68%Cor e Forma:SolidPeso molecular:489.95Roxifiban acetate
CAS:<p>Roxifiban acetate（DMP 754 acetate） is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in</p>Fórmula:C23H33N5O8Pureza:97.91% - 98.36%Cor e Forma:SolidPeso molecular:507.54AZD4573
CAS:<p>AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.</p>Fórmula:C22H28ClN5O2Pureza:99% - 99.51%Cor e Forma:SolidPeso molecular:429.94BDP9066
CAS:<p>BDP9066 is a potent and selective MRCK inhibitor, inhibits MRCKβ and MRCKα/β, and can be used for the prevention and treatment of skin cancer.</p>Fórmula:C20H24N6Pureza:98.18%Cor e Forma:SolidPeso molecular:348.44B I09
CAS:<p>B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells.</p>Fórmula:C16H17NO5Pureza:98.80%Cor e Forma:SolidPeso molecular:303.31CF53
CAS:<p>CF53: potent, selective oral BET inhibitor; Ki <1 nM, Kd 2.2 nM, IC50 2 nM for BRD4 BD1; high affinity for BRD2/3/4/BRDT; effective anti-tumor agent.</p>Fórmula:C24H25N7O2Pureza:99.72%Cor e Forma:SolidPeso molecular:443.5(R)-Simurosertib
CAS:<p>(R)-Simurosertib ((R)-TAK-931) is an inhibitor of the ATP-competitive cell division cycle 7 (CDC7) kinase.</p>Fórmula:C17H19N5OSPureza:99.89%Cor e Forma:SolidPeso molecular:341.43PD-L1-IN-3
CAS:<p>PD-L1-IN-3 is a PD-1/PD-L1 inhibitor for the study of tumors and immune diseases.</p>Fórmula:C19H15ClFN2OSPureza:99.47%Cor e Forma:SoildPeso molecular:373.85CCT129202
CAS:<p>CCT129202 is an ATP-competitive pan-Aurora inhibitor for Aurora A, Aurora B and Aurora C with IC50 of 0.042 μM, 0.198 μM and 0.227 μM, respectively.</p>Fórmula:C23H25ClN8OSPureza:98.14%Cor e Forma:SolidPeso molecular:497.02LNA-Adenosine
CAS:<p>LNA-Adenosine (LNA-A) is a nucleoside analogue that acts as a ligand for adenosine A3 receptors.</p>Fórmula:C11H13N5O4Pureza:99.15%Cor e Forma:SolidPeso molecular:279.25αvβ1 integrin-IN-1
CAS:<p>αvβ1 integrin-IN-1 is a potent and selective inhibitor of αvβ1 integrin (IC50 of 0.63 nM) with antifibrotic effects.</p>Fórmula:C26H34N6O6SPureza:99.74% - >99.99%Cor e Forma:SolidPeso molecular:558.65Sorivudine
CAS:<p>Sorivudine (BV-araU) is an antiviral blocking DNA synthesis in viruses like varicella, HSV-1, and Epstein-Barr.</p>Fórmula:C11H13BrN2O6Pureza:99.74%Cor e Forma:SolidPeso molecular:349.13Lomibuvir
CAS:<p>Lomibuvir (VCH-222, VX-222) is an allosteric inhibitor of HCV NS5B with Kd 17 nM, blocks RNA elongation, EC50 5.2 nM for 1b/Con1.</p>Fórmula:C25H35NO4SPureza:99.83%Cor e Forma:SolidPeso molecular:445.61Aurora inhibitor 1
CAS:<p>Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).</p>Fórmula:C23H25N9SPureza:98%Cor e Forma:SolidPeso molecular:459.57CDK2/4-IN-2
CAS:<p>CDK2/4-IN-2 (compound 56) serves as a dual inhibitor for CDK2 and CDK4, exhibiting an IC50 of less than 100 nM. It is applicable in cancer research.</p>Fórmula:C18H20F3N7O3S2Cor e Forma:SolidPeso molecular:503.52CDK2-IN-40
CAS:<p>CDK9-IN-40 is an inhibitor of CDK2 (Cyclin-dependent kinase 2). It effectively inhibits CDK2/Cyclin E1, with an IC50 of ≤ 10 nM.</p>Fórmula:C16H21N7O2Cor e Forma:SolidPeso molecular:343.384MU147
CAS:<p>MU147 is an MRE11 nuclease inhibitor and chemical probe with anticancer properties, exhibiting lethal effects on Ehrlich ascites tumor cells both in vivo and in vitro. It disrupts the MRE11 nuclease-dependent double-strand break repair mechanism without impairing ATM activation. Additionally, MU147 damages the degradation of nascent strands at stalled replication forks and selectively affects BRCA2-deficient cells.</p>Fórmula:C19H13N3O3SCor e Forma:SolidPeso molecular:363.39CHK1 inhibitor
CAS:<p>CHK1 inhibitor (GDC-0575 analog) is a CHK1 inhibitor.</p>Fórmula:C17H21BrN4OPureza:98%Cor e Forma:SolidPeso molecular:377.28TA-316
CAS:<p>Agent induces megakaryocytes/platelets from stem cells to treat thrombopenia.</p>Fórmula:C28H25BrN4O5S2Pureza:98%Cor e Forma:SolidPeso molecular:641.56TREX1-IN-3
CAS:<p>TREX1-IN-3 (Compound 95) is an inhibitor of TREX1 and TREX2, with an IC50 of less than 0.1 μM for TREX1 and less than 1 μM for TREX2, as well as an EC50 of less than 1 μM for HCT116 cells. It is applicable for research in the field of cancer.</p>Fórmula:C24H19ClN6O4Cor e Forma:SolidPeso molecular:490.898HPH-15
CAS:<p>HPH-15 is an anti-cell migration compound that inhibits cell movement by binding to hnRNP U or suppressing TGF-β. Additionally, it prevents epithelial-to-mesenchymal transition (EMT). HPH-15 holds potential for research in areas such as anti-tumor metastasis and anti-fibrosis.</p>Fórmula:C19H31N3S4Cor e Forma:SolidPeso molecular:429.73DNA gyrase B-IN-1
<p>DNA gyrase B-IN-1, a potent inhibitor of P. aeruginosa DNA gyrase B, has IC50 of 2.2 μM with high affinity and stability.</p>Fórmula:C23H18ClF3N6O4SCor e Forma:SolidPeso molecular:566.94MY05
CAS:<p>MY05 selectively targets c-MYC within cells and disrupts the interaction between MYC and MAX. It binds to intracellular c-MYC, modulating its thermal stability, reducing the transcriptional targets of c-MYC, and exhibiting anticancer activity (TNBC, triple-negative breast cancer).</p>Fórmula:C19H11ClN4OCor e Forma:SolidPeso molecular:346.77PD-L1-IN-7
CAS:<p>PD-L1-IN-7 (compound CB31) serves as a PD-L1 inhibitor, effectuating PD-L1 internalization and retention within cells. It restrains the PD-1/PD-L1 interaction (IC 50: 0.2 nM), alters glycosylation patterns, and facilitates PD-L1 degradation. Additionally, PD-L1-IN-7 enhances T cell infiltration, boosts T cell function, and augments the capacity to destroy tumor cells.</p>Fórmula:C46H50N6O7Cor e Forma:SolidPeso molecular:798.93GTSE1-IN-1
CAS:<p>GTSE1-IN-1 (compound Y18), an orally active GTSE1 inhibitor, exhibits notable anticancer properties. It effectively represses the proliferation of cancer cells by downregulating GTSE1 transcription and expression, which leads to DNA damage and promotes persistent cell cycle arrest and cellular senescence. Moreover, GTSE1-IN-1 substantially reduces the adhesion, migration, and invasion of colorectal cancer HCT116 cells and non-small cell lung cancer A549 cells in vitro.</p>Fórmula:C21H24FN7Cor e Forma:SolidPeso molecular:393.46Zeltociclib
CAS:<p>Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.</p>Fórmula:C18H20F3N4O2PCor e Forma:SolidPeso molecular:412.346TY-011
CAS:<p>TY-011 is an inhibitor of Aurora A/B kinases. This compound induces DNA damage and cell apoptosis (Apoptosis) in human gastric cancer cells by promoting abnormal microtubule-kinetochore attachments, effectively suppressing cancer cell proliferation. The IC50 values for TY-011 in human gastric cancer cell lines range from 0.11-4.49 μM. It is utilized in research focused on gastric cancer.</p>Fórmula:C18H16ClN5Cor e Forma:SolidPeso molecular:337.81ddCTP trisodium
<p>ddCTP trisodium, an HIV reverse transcriptase target, aids AIDS research and DNA sequencing as a ddNTP.</p>Fórmula:C9H13N3Na3O12P3Cor e Forma:SolidPeso molecular:517.1FR-β ligand 1
CAS:<p>FR-β ligand 1 (III) is a ligand that specifically targets folate receptors, exhibiting antitumor activity, high selectivity, and strong affinity.</p>Fórmula:C22H25N5O6Cor e Forma:SolidPeso molecular:455.46CHK1-IN-4
CAS:<p>CHK1-IN-4 is a potent inhibitor of checkpoint kinase 1 (chk1) and potently inhibits chk1 phosphorylation in the tumor cells with anti-tumor activity.</p>Fórmula:C18H18BrN7O2Pureza:98%Cor e Forma:SolidPeso molecular:444.29DL-Alanosine
CAS:<p>DL-Alanosine is an amino acid analog with antitumor activity.</p>Fórmula:C3H7N3O4Cor e Forma:SolidPeso molecular:149.105LIMK1 inhibitor 1
CAS:<p>LIMK1 inhibitor1 (compound 24) is a LIMK1 inhibitor, potentially useful for cancer research.</p>Fórmula:C12H15N3S2Cor e Forma:SolidPeso molecular:265.398RNAP-σ interaction inhibitor-1
CAS:<p>RNAP-σ interaction inhibitor-1 (compound 5d) acts as an inhibitor of the interaction between RNA polymerase and the sigma factor. It exhibits activity against Streptococci with a minimum inhibitory concentration (MIC) ranging from 1-2 µg/mL.</p>Fórmula:C19H11Cl3N2O6S2Cor e Forma:SolidPeso molecular:533.79TREX1-IN-4
CAS:<p>TREX1-IN-4 (Compound 96) is an inhibitor of TREX1 and TREX2, exhibiting an IC50 of less than 0.1 μM for TREX1 and an IC50 of less than 1 μM for TREX2. It has an EC50 ranging from 0.1 to 10 μM in HCT116 cells. TREX1-IN-4 is applicable for research in the field of cancer.</p>Fórmula:C24H19ClN6O4Cor e Forma:SolidPeso molecular:490.898Cdc7-IN-8
CAS:<p>Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)</p>Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.40Pseudouridine 5'-OTBDPS
CAS:<p>Pseudouridine5'-OTBDPS [5-(5-O-TBDPS-β-D-ribofuranosyl)uracil] is an intermediate of Pseudouridine.</p>Fórmula:C25H30N2O6SiCor e Forma:SolidPeso molecular:482.60APE1-IN-3
CAS:<p>APE1-IN-3 (Compound 1), an APE1 inhibitor, is utilized in cancer research.</p>Fórmula:C17H16O4Cor e Forma:SolidPeso molecular:284.31GSK3-IN-10
CAS:<p>GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.</p>Fórmula:C17H18F2N4O3Cor e Forma:SolidPeso molecular:364.347MU1409
CAS:<p>MU1409 is an MRE11 nuclease inhibitor with an IC50 of 12.1 μM. It also inhibits FEN1 and EXO1, with IC50 values of 24.2 μM and 176.4 μM, respectively. MU1409 impacts cellular DNA repair and prevents the degradation of stalled replication forks in BRCA2-deficient cells, making it a promising candidate for studying BRCA2 mutation-induced cancers.</p>Fórmula:C20H14BrN3O3SCor e Forma:SolidPeso molecular:456.312Aurora/LIM kinase-IN-1
<p>Aurora/LIM kinase-IN-1 (Compound F114) is a dual inhibitor targeting aurora and lim kinases, potentially useful in GBM cancer treatment efforts.</p>Fórmula:C16H20N6OCor e Forma:SolidPeso molecular:312.37N6-Benzoyl-2'-deoxy-3'-O-DMT-adenosine
CAS:<p>N6-Benzoyl-2'-deoxy-3'-O-DMT-adenosine is a nucleoside analog that resembles the natural nucleotide adenosine in structure. It acts as an activator of ribonucleotide reductase, facilitating the conversion of ribonucleotides into deoxyribonucleotides.</p>Fórmula:C38H35N5O6Cor e Forma:SolidPeso molecular:657.714TASIN-30
CAS:<p>TASIN-30 is an inhibitor of EBP, exhibiting a competitive EC50 value of 0.097 μM, and possesses a competitive EC50 value of 50 μM against DHCR7.</p>Fórmula:C18H30N2O3SCor e Forma:SolidPeso molecular:354.51DYRK1-IN-1
CAS:<p>DYRK1-IN-1: Selective DYRK1A inhibitor with IC50 of 220 nM, good permeability, CNS penetrant for research, no P-glycoprotein issues.</p>Fórmula:C12H12N6Cor e Forma:SolidPeso molecular:240.26LNA-UTP
CAS:<p>LNA-UTP is a nucleotide analogue used in the synthesis of oligonucleotides.</p>Fórmula:C10H15N2O15P3Cor e Forma:SolidPeso molecular:496.152'-F-AMP
CAS:<p>2'-F-AMP is a nucleotide analogue used in the synthesis of oligonucleotides.</p>Fórmula:C10H13FN5O6PPeso molecular:349.21CDK12/13 ligand 1
CAS:<p>ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.</p>Fórmula:C26H26BrN5OCor e Forma:SolidPeso molecular:504.42
